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Objectives. This study sought to investigate the impact of
surgical revascularization on outcome after myocardial infarc-
tion.
Background. Small variations in rates of coronary artery
bypass graft surgery (CABG) were noted among thrombolytic
regimens in the Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries (GUSTO)
trial, prompting the question of whether survival differences were
partly related to differences in CABG rates.
Methods. Patients in the GUSTO trial were randomized to one
of four thrombolytic strategies. Of 40,861 patients with complete
data, 3,526 underwent surgical revascularization during their
initial hospital admission. Thirty-day and 1-year mortality rates
were estimated using Kaplan-Meier techniques, and the impact of
CABG as a time-dependent covariate on death was evaluated
using a Cox survival model, adjusting for baseline prognostic
factors.
Results. The median time from study enrollment to CABG was
7 days across treatment groups. A 15% reduction in mortality for
the tissue-type plasminogen activator (t-PA)–treated group was
evident by the seventh day. Bypass surgery was a significant
independent predictor of 30-day mortality (risk ratio 1.87) and a
weaker predictor of 1-year mortality (risk ratio 1.21). Operative
mortality was highest in patients with acute mitral regurgitation,
ventricular septal defect or poor left ventricular function and in
those undergoing CABG within the first 4 days of randomization.
Conclusions. The survival benefit of accelerated t-PA was not
related to surgical revascularization. Bypass surgery was associ-
ated with excess mortality in the first year, but the added
short-term mortality associated with CABG may be balanced by
anticipated long-term benefit in specific groups of patients.
(J Am Coll Cardiol 1997;29:240–9)
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The Global Utilization of Streptokinase and Tissue Plasmino-
gen Activator (t-PA) for Occluded Coronary Arteries
(GUSTO) trial (1) demonstrated that accelerated administra-
tion of t-PA resulted in improved survival compared with
streptokinase and that this survival advantage is related to
earlier infarct-related artery patency and enhanced perfusion
(2). Initial reports from the trial (3) also noted small differ-
ences in rates of coronary artery bypass surgery (CABG)
among treatment regimens and raised the question of whether
survival differences were attributable to differences in opera-
tion rates.
The large population of the GUSTO trial (41,021 patients
admitted to 1,081 institutions in 15 countries) offered the
opportunity to examine relations between baseline clinical and
angiographic findings and early surgical revascularization. We
attempted to define the impact of surgical revascularization on
mortality and other clinical outcomes and to differentiate
between outcome effects attributable to CABG procedures
and those related to the thrombolytic strategy and patient
baseline characteristics.
Methods
Patient population. Enrollment criteria for the GUSTO
trial have been previously described (1). The protocol was
approved by the institutional review board at each study center
and patient written informed consent was obtained before
randomization. The 41,021 patients were enrolled between
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December 27, 1990 and February 22, 1993, and data from
40,861 patients were complete for inclusion in this study
(99.6%). Data from the remaining GUSTO patients (0.4%)
were incomplete or inadequate for the purposes of this study,
and these patients were excluded from analyses. For the
purposes of the present report, patients were classified into two
groups: those undergoing CABG at any time during the initial
hospital period and those not undergoing CABG.
Study protocol. Patients were randomly assigned to one of
four thrombolytic strategies: 1) 1.5 million U of streptokinase
(SK) over a 60-min period with 12,500 U of subcutaneous (SQ)
heparin twice daily beginning 4 h after the initiation of
thrombolytic therapy; 2) 1.5 million U of SK with intravenous
(IV) heparin administered as a bolus dose of 5,000 U followed
by an infusion of 1,000 U/h; 3) t-PA given as a bolus dose of
15 mg followed by 0.75 mg/kg body weight over 30 min
(maximal 50 mg) and then 0.5 mg/kg infused over 60 min
(maximal 35 mg) with IV heparin administered as in strategy 2;
or 4) combination therapy with 1.0 million U of SK adminis-
tered over a 60-min period concomitantly with t-PA (1.0 mg/kg
with 10% given as a bolus) along with IV heparin.
Aspirin and atenolol were administered as specified by the
study protocol (1). All other medications and interventions,
including cardiac catheterization and surgical or percutaneous
revascularization, were at the discretion of the investigator.
End points. The primary end point was death from any
cause within 30 days of enrollment. The following additional
end points were prospectively defined and assessed in-hospital:
hemorrhagic or nonhemorrhagic stroke; death or nonfatal
stroke; death or nonfatal hemorrhagic stroke; death or nonfa-
tal disabling stroke; reinfarction; ischemia; shock; and conges-
tive heart failure or pulmonary edema. Reinfarction was deter-
mined by the presence of at least two of following criteria:
recurrent ischemia lasting.15 min; new ST-T wave changes or
new Q waves; reelevation of cardiac enzyme levels above the
normal limit or further elevation .20% above normal; or
angiographic reocclusion of a previously patent infarct-related
artery. Shock was defined as a systolic blood pressure
,90 mm Hg unresponsive to fluid therapy associated with
signs of hypoperfusion or cardiac index #2.2 liters/min per m2.
Stroke was characterized as new neurologic deficits lasting
.24 h or resulting in death. Congestive heart failure was defined
as signs or symptoms of congestion or low cardiac output.
Recurrent ischemia was defined as symptoms, electrocardio-
graphic changes or new hypotension, pulmonary edema or
murmur thought to represent myocardial ischemia. The date of
the first episode of each end point was recorded.
Data management and statistical analysis. Demographic
and clinical data were collected on standardized case report
forms. Definitions of variables and written instructions were
provided for completion of forms. Quality checks were con-
ducted regularly and missing or inconsistent data values were
investigated. Data from a randomly derived and representative
sample (12%) of forms were verified from the hospital medical
record.
Baseline characteristics of the surgical and nonsurgical
treatment groups were compared for categoric data by sum-
marizing frequencies and percentages and for continuous data
as mean value 6 SD or median (25th and 75th percentiles).
Binary outcome variables were similarly reported as per-
centages for in-hospital events. Kaplan-Meier techniques were
applied to estimate the rate of CABG from 7 to 30 days of
enrollment. The raw event rates included a number of medi-
cally treated patients who died early, before having the oppor-
tunity for surgical therapy. To adjust for bias resulting from the
inclusion of the early deaths in the nonsurgical treatment
group, outcome event rates were also calculated after subtract-
ing from each group those patients who died or who had
experienced the given outcome event before specific time
points.
Mortality risk predictions were calculated on the basis of a
previously described survival model that includes clinical char-
acteristics measured at the time of entry into the trial and
found to be predictive of mortality (4). The distribution of
predicted risk across the patient groups was illustrated by
plotting the cumulative distribution of predicted risk of 30-day
death for the patients treated with and without CABG.
Mortality during the 30-day and 1-year follow-up periods
was depicted using Kaplan-Meier curves. The impact of CABG
on time until death after acute myocardial infarction (MI) was
further evaluated by construction of a Cox survival model,
adjusting for known baseline prognostic factors and examining
the effect of operation as a time-dependent covariate. In this
analysis, patients eventually treated surgically were considered
to be members of the medically treated group until the day of
operation. At that point, they were crossed over to the
surgically treated group.
Multivariable regression analysis was used to construct a
model to examine the relation between baseline clinical char-
acteristics and death within 30 days of randomization for
patients who underwent a CABG during the hospital period.
Characteristics of the variables considered for the model were
reported as frequencies and percentages for categoric data,
and the median (25th, 75th percentiles) percentiles were used
for continuous variables. Sixty-five studies that were missing
the end point or all catheterization data were excluded. All
remaining 3,461 studies were used in the logistic regression
model. A method for simultaneous imputation of predictor
variables based on the concepts of maximal generalized vari-
ance and canonical variables was used to estimate missing
predictor variables to allow for the analysis of all patients. The
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
IV 5 intravenous
MI 5 myocardial infarction
SK 5 streptokinase
SQ 5 subcutaneous
t-PA 5 tissue-type plasminogen activator
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variables were analyzed to assess the assumption that the log
odds of death is linearly related to the dependent variables,
and adjustments were made when necessary. The receiver
operating characteristic curve was used to show model perfor-
mance. This index measures the concordance between predic-
tive values and actual outcomes. The model was calibrated
using a graph of the average predicted values versus the
observed mortality rates across deciles of risk.
Results
Patient characteristics. Nine percent of patients treated
with t-PA and 8.3% of those treated with SK (IV and SQ
heparin treatment groups combined) underwent surgical re-
vascularization during the initial hospital period (p 5 0.050).
Baseline demographic characteristics and presenting features
of patients referred for CABG were comparable to those
treated nonsurgically, although there were small differences in
individual variables (Table 1). Overall, patients who underwent
CABG were slightly more likely to have features consistent
with long-standing cardiovascular disease (history of angina or
previous MI; comorbid disorders associated with cardiovascu-
lar disease, including hypertension, diabetes mellitus and hy-
percholesterolemia; or a positive family history). Figure 1
shows a summary of mortality risk predictions for the surgical
and nonsurgical treatment groups. Because the nonsurgically
treated group included more very low risk and extremely high
risk patients, analysis of overall risk factor characteristics led to
a higher mean predicted (7.1% vs. 6.6%) but a lower median
predicted (3.3% vs. 3.9%) 30-day mortality.
Catheterization results were available for 22,640 patients
(55% of the total) and are included in Table 2. Patients
referred for CABG had more extensive disease and a higher
rate of multivessel involvement than those treated nonsurgi-
cally (p, 0.001). The patients treated with CABG were similar
to the nonsurgical population in terms of relative distribution
of infarct-related vessels and patency of the infarct-related
artery at the time of first catheterization but tended to have a
slightly lower median left ventricular ejection fraction (50%)
than the nonsurgical group (52%) (p , 0.001).
Timing of surgical intervention. The time from random-
ization to CABG for each treatment group is shown in Table 3.
There were no significant differences in the timing of CABG.
Thirty-day mortality as a function of time between random-
ization and CABG is displayed in Figure 2. Mortality was
substantial in patients undergoing CABG within the first 2 days
but decreased rapidly after that. There was no apparent
relation between time from onset of symptoms to CABG and
mortality beyond the third day.
Figure 3 illustrates the mortality data for each of the
treatment groups compared with the occurrence of CABG
procedures. A statistically significant difference in mortality
was observed between the accelerated t-PA group and the two
SK regimens, as has been previously reported (1). A reduction
in mortality for the t-PA–treated group is evident within 24 h
of randomization. The reduction in mortality in the t-PA group
becomes more substantial over the first week after study entry
and persists through the 30-day follow-up period. Patients
underwent CABG procedures at a similar rate during the first
week after study enrollment, regardless of treatment group
assignment. There was a small excess of CABG procedures in
the t-PA–treated group from 1 week until the 30-day end point.
Thirty-day clinical outcomes. Unadjusted outcome event
rates in the CABG and non-CABG groups are presented in
Table 4. Patients with acute MI complicated by ventricular
arrhythmias, hypotension and mechanical disturbances, such as
mitral regurgitation and acute ventricular septal defects, com-
prised a slightly higher percentage of the CABG group than
Table 1. Baseline Characteristics of Surgically and Nonsurgically
Treated Patients After Acute Myocardial Infarction
Clinical Characteristic
No CABG
(n 5 37,335)
CABG
(n 5 3,526)
Age (yr)
Mean 6 SD 60.8 6 12.1 61.9 6 10.2
Median (25th, 75th percentiles) 61 (52, 70) 63 (55, 70)
Weight (kg)
Mean 6 SD 79.2 6 15.7 81.4 6 15.0
Median (25th, 75th percentiles) 78 (69, 88) 80 (71, 90)
Male 27,839 (75%) 2,728 (77%)
Hypertension 13,890 (37%) 1,607 (46%)
Diabetes 5,365 (14%) 622 (18%)
Current smoker 16,224 (44%) 1,239 (35%)
History of smoking 25,767 (70%) 2,368 (68%)
Hypercholesterolemia 12,106 (34%) 1,438 (42%)
Family history 14,822 (41%) 1,696 (50%)
Previous MI 5,859 (16%) 823 (23%)
Previous angina 13,418 (36%) 1,587 (45%)
Previous CABG 1,584 (4%) 193 (5%)
Previous PTCA 1,440 (4%) 200 (6%)
Killip class
I 31,700 (85%) 3,015 (86%)
II 4,691 (13%) 419 (12%)
III 497 (1%) 46 (1%)
IV 286 (1%) 23 (1%)
MI location
Anterior 14,486 (39%) 1,425 (41%)
Inferior 21,444 (58%) 1,988 (56%)
Other 1,295 (3%) 100 (3%)
Onset of symptoms to treatment (h)
Mean 6 SD 3.10 6 1.61 3.07 6 1.77
Median (25th, 75th percentiles) 2.8 (2.0, 3.9) 2.7 (1.9, 3.8)
SBP (mm Hg)
Mean 6 SD 129.1 6 23.4 128.5 6 22.8
Median (25th, 75th percentiles) 130 (112, 144) 128 (112, 142)
DBP (mm Hg)
Mean 6 SD 78.1 6 14.9 77.5 6 15.2
Median (25th, 75th percentiles) 80 (70, 90) 78 (68, 88)
Pulse (beats/min)
Mean 6 SD 75.4 6 17.6 75.5 6 17.1
Median (25th, 75th percentiles) 74 (62, 86) 74 (63, 86)
Continuous variables are shown as mean value 6 SD or median (25th, 75th
percentiles). Discrete variables are shown as absolute numerical frequency
(relative %). CABG 5 coronary artery bypass graft surgery; DBP 5 diastolic
blood pressure; MI5myocardial infarction; PTCA5 percutaneous transluminal
coronary angioplasty; SBP 5 systolic blood pressure.
242 TARDIFF ET AL. JACC Vol. 29, No. 2
CABG AFTER MI IN GUSTO February 1997:240–9
Figure 1. Cumulative distribution of
predicted probabilities of 30-day mor-
tality: CABG-treated versus non–
CABG-treated patients. Distribution
of patients over the range of predicted
probabilities is shown.
Table 2. Anatomic Characteristics of Coronary Artery Disease in Surgically and Nonsurgically Treated
Patients After Acute Myocardial Infarction
Angiographic Characteristic
No CABG
(n 5 19,167 [51%])
CABG
(n 5 3,473 [99%])
IRA
LAD 6,867 (36%) 1,287 (38%)
LCx 2,294 (12%) 321 (9%)
RCA 8,631 (45%) 1,528 (45%)
LMCA 44 (0.2%) 49 (1.4%)
Graft 313 (2%) 71 (2%)
Unknown 793 (4%) 174 (5%)
None 31 (0.2%) 1 (,0.1%)
No. of diseased vessels .50% diameter stenosis
0 1,617 (10%) 14 (0.5%)
1 8,377 (52%) 352 (12%)
2 4,182 (26%) 1,075 (38%)
3 1,921 (12%) 1,424 (50%)
TIMI flow grade at 1st cath
0 2,164 (19%) 327 (19%)
1 1,218 (11%) 218 (13%)
2 2,512 (22%) 436 (25%)
3 5,702 (49%) 753 (43%)
Open 9,450 (72%) 1,433 (70%)
Closed 3,658 (28%) 617 (30%)
IRA % stenosis at 1st cath
0–50 1,911 (10%) 31 (1%)
51–75 2,279 (13%) 232 (7%)
76–95 9,024 (50%) 1,942 (59%)
96–99 1,692 (9%) 422 (13%)
100 3,309 (18%) 656 (20%)
LVEF at 1st cath (%)*
Mean 6 SD 52.2 6 12.9 50.2 6 13.1
Median (25th, 75th percentiles) 52 (44, 60) 50 (40, 60)
*n 5 13,348 for nonsurgical population, 2,538 for coronary artery bypass graft surgery (CABG) group. Discrete
variables are shown as absolute numerical frequency (relative %), unless otherwise indicated. cath 5 catheterization;
IRA 5 infarct-related artery; LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary artery;
LMCA 5 left main coronary artery; LVEF 5 left ventricular ejection fraction; RCA 5 right coronary artery; TIMI 5
thrombolysis in myocardial infarction.
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the non-CABG group (p, 0.001 for all). The overall incidence
of stroke was similar in the two groups (p 5 0.188), although
the CABG group was more likely to have a nonhemorrhagic
stroke. Nearly all the recurrent ischemia and reinfarction
events antedated the surgical procedure (Table 5). Congestive
heart failure and pulmonary edema occurred principally in the
preoperative and immediate perioperative periods. The timing
of complications with respect to the surgical procedure is not
known for outcomes reported in Table 4 but not included in
Table 5.
On the basis of these unadjusted outcome data, patients
undergoing CABG appeared significantly less likely than those
not undergoing CABG to experience a fatal event in the 30-day
follow-up period. However, as evident from Figure 3, a signif-
icant proportion of the deaths in all groups occurred within the
first 24 h. Outcome event rates adjusted to eliminate patients
who died before 24, 48, 72 and 96 h after onset of symptoms
are shown in Table 6. When patients who died within the first
4 days of onset of symptoms were not included in the analyses,
CABG was associated with a higher 30-day mortality than
nonsurgical treatment.
Coronary artery bypass graft surgery was a predictor of
30-day mortality when examined as a time-dependent covariate
in a Cox survival model (chi-square value 53.0, p , 0.001).
Without adjusting for other prognostic factors, the likelihood
of death increased by a factor of 1.94 (1.64, 2.28) with the
occurrence of CABG (beta value 0.6615). When the model was
adjusted to compensate for differences in baseline character-
istics that have been found to be predictive of death (4), CABG
remained an independent predictor of 30-day mortality (chi-
square value 49, p, 0.001). The risk ratio was 1.87 (1.59, 2.20)
in this adjusted model (CABG beta value 0.627).
One-year mortality outcomes. Figure 4 illustrates survival
curves for the surgical and nonsurgical groups plotted over the
period from randomization to 1 year. An excess early death
rate is evident in both groups. A third plot shows survival over
the period from 8 days to 1 year in the nonsurgically treated
patients who were alive at 8 days, the mean time of CABG.
From 30 days to 1 year, the curves parallel each other and
begin to converge.
The Cox model was also extended to include 1-year mor-
tality outcome data. Bypass surgery remained an independent
but weaker predictor of 1-year mortality (unadjusted chi-
square value 13, p , 0.001; adjusted chi-square value 7, p ,
0.006) and was associated with less excess risk (unadjusted beta
value 0.2500, risk ratio 1.28 [1.12, 1.47]; adjusted beta value
0.1868, risk ratio 1.21 [1.06, 1.38]).
Risks factors for operative mortality. In a multivariable
analysis, the risk of death after CABG and within 30 days of
enrollment was directly related to the development of an acute
ventricular septal defect or acute mitral regurgitation and
inversely related to left ventricular ejection fraction and the
time from enrollment until operation (Table 7). A substantial
decrease in mortality rate was seen as time until operation
Figure 2. Mortality as a function of
time from onset of symptoms to
CABG. Thirty-day mortality rate is
shown as a function of time between
onset of symptoms and time of sur-
gical procedure.
Table 3. Timing of Coronary Artery Bypass Graft Procedures
Relative to Onset of Symptoms
Treatment
Days to CABG
Mean 6 SD
Median
(25th, 75th
percentiles)
t-PA 8.7 6 6.3 8 (5, 11)
SK1IV heparin 8.36 5.6 7 (5, 11)
SK and t-PA1IV heparin 8.5 6 6.5 8 (5, 11)
SK1SQ heparin 8.66 6.9 7 (4, 11)
Total 8.5 6 6.3 7 (5, 11)
Days to CABG 5 time from onset of symptoms until coronary artery bypass
graft surgery (CABG). IV 5 intravenous; SK 5 streptokinase; SQ 5 subcuta-
neous; t-PA 5 accelerated tissue-type plasminogen activator.
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approached 4 days; a slight decrease was seen thereafter. The
effects of these variables were independent of and in addition
to the influence of clinical characteristics measured at the time
of study entry and previously found to be predictive of
mortality in the GUSTO population (the logit GUSTO). The
infarct-related artery and number of diseased vessels were not
significant predictors of mortality, nor were regional differ-
ences in perioperative mortality observed.
Discussion
Bypass surgery and thrombolytic strategy. This analysis of
the GUSTO trial data base confirms that the observed benefit
of accelerated t-PA was not due to the increased use of
revascularization. An in-depth examination of the data dem-
onstrated that the slightly increased frequency of CABG in the
t-PA group did not explain the mortality differences observed
between the t-PA– and SK-treated groups. A 15% statistically
significant reduction in mortality afforded by t-PA was appar-
ent within the first week of enrollment, during which time the
proportion of patients undergoing CABG was not different
among the four treatment groups. The early divergence of the
survival curves eliminates surgical revascularization as an
explanation for the survival benefit of accelerated t-PA.
A slightly higher rate of CABG in the t-PA–treated patients
was observed later in the study period. This higher procedure
rate may be attributed to the survival advantage of t-PA and
larger number of surviving patients available for referral.
Patients treated with t-PA had better preservation of left
ventricular function that those treated with SK (2), which may
have also improved their likelihood of referral for CABG. We
cannot exclude a role for surgical revascularization as an
important part of the strategy for preserving myocardial func-
tion after thrombolysis with t-PA.
Figure 3. Thirty-day mortality rate and
CABG procedures by treatment group.
Kaplan-Meier mortality estimates for
three of the four treatment groups are
plotted with an actuarial analysis over the
30-day follow-up period and are shown
with cumulative percentage of patients in
each group undergoing CABG over the
same time period.
Table 4. Clinical Outcomes in Surgically and Nonsurgically Treated
Patients After Acute Myocardial Infarction
Clinical Event
No CABG
(n 5 37,335)
CABG
(n 5 3,526)
Fever, chills, allergic reaction 1,655 (4%) 168 (5%)
Anaphylaxis 192 (0.5%) 19 (0.5%)
Hypotension 4,303 (12%) 560 (16%)
AV block 3,045 (8%) 330 (9%)
Sustained ventricular tachycardia 2,241 (6%) 276 (8%)
Ventricular fibrillation 2,412 (6%) 318 (9%)
Asystole 2,173 (6%) 161 (5%)
Atrial fibrillation/flutter 3,022 (8%) 793 (23%)
Acute mitral regurgitation 463 (1%) 105 (3%)
Acute VSD 158 (0.4%) 36 (1.0%)
Tamponade 274 (1%) 37 (1%)
Worst Killip class
I 24,912 (67%) 1,732 (50%)
II 8,966 (24%) 1,303 (37%)
III 1,548 (4%) 255 (7%)
IV 1,673 (5%) 199 (6%)
In-hospital mortality 2,541 (6.8%) 151 (4.3%)
30-day mortality 2,683 (7.2%) 144 (4.1%)
Stroke 532 (1.4%) 60 (1.7%)
Hemorrhagic 263 (0.7%) 5 (0.1%)
Nonhemorrhagic 199 (0.5%) 48 (1.4%)
Conversions 30 (0.1%) 4 (0.1%)
Unknown 40 (0.1%) 3 (0.1%)
Death or nonfatal stroke 2,976 (8.0%) 199 (5.7%)
Death or hemorrhagic stroke 2,788 (7.5%) 147 (4.2%)
Death or disabling stroke 2,853 (7.6%) 181 (5.1%)
Reinfarction 1,332 (3.6%) 290 (8.3%)
Ischemia 6,823 (18%) 1,290 (37%)
Shock 2,150 (6%) 281 (8%)
CHF or PE 5,833 (16%) 779 (22%)
Outcome event rates are absolute numerical frequencies (relative %). AV 5
atrioventricular; CABG 5 coronary artery bypass graft surgery; CHF 5 conges-
tive heart failure; PE 5 pulmonary edema; VSD 5 ventricular septal defect.
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Clinical outcomes. Excess mortality in the first year after
operation was observed for patients treated with CABG during
the index hospital period after acute MI. The 30-day mortality
rate for the nonsurgical group was lower than that for patients
undergoing CABG when deaths that occurred before the time
that surgical revascularization would normally be considered
were eliminated from the analysis. When only deaths occurring
after 96 h were considered, the mortality rates were 3.1% for
the surgically treated group versus 2.1% for patients not
surgically treated. These findings are comparable to previously
reported mortality rates for CABG in the setting of acute MI
(5,6).
Coronary artery bypass graft surgery was an independent
predictor of mortality at 30 days and at 1 year in a time-
dependent covariate model adjusted for baseline characteris-
tics that have previously been shown (4) to be predictive of
mortality. A recently published systematic overview of ran-
domized trials of CABG versus medical therapy demonstrated
(7) that in predominantly elective CABG, the benefit does not
become evident until after the first year of randomization. At
1 year after randomization to CABG, the rate of infarction or
death reported in the overview was 11.6% in the CABG group
and 8.0% in the medically treated group. A similar pattern was
observed in the Duke experience (8,9). As in the GUSTO trial,
those studies found a small but consistent excess mortality in
the perioperative period, with survival curves converging over
the first year, crossing just after the first year and then showing
a benefit of operation after that time. The results presented in
this study should not be interpreted as indicating that the
surgical choice in these patients was incorrect; rather, the full
impact of treatment selection will be discernible only with
longer term follow-up.
Risk factors for early mortality after CABG after throm-
bolysis include mechanical complications of acute MI (ventric-
ular septal defect or acute mitral regurgitation), poor systolic
function (decreased left ventricular ejection fraction) and
operation within the first few days of symptom onset. The
appropriate timing of operation after acute MI is a complex
issue. These and other recent data (10) support the concept
that the myocardium benefits from an initial period of stabili-
zation. However, patients referred for early operation were
most likely to have experienced acute deterioration immedi-
ately before CABG, and it is difficult to fully account for all
factors contributing to the higher risk associated with operat-
Table 5. Clinical Outcome Events in Patients Undergoing Coronary Artery Bypass Graft Surgery: Timing Relative to Operation
Event
No. of
Pts
Before
CABG Same Day
After
CABG
CABG Date
Unknown
Event Date
Unknown
Death 144 0 30 (21%) 114 (79%) 0 0
Shock 281 130 (46%) 124 (44%) 26 (9%) 0 1
Reinfarction 290 183 (63%) 88 (30%) 16 (6%) 2 1
Stroke 60 10 (17%) 12 (20%) 36 (61%) 0 2
Ischemia 1290 1,065 (83%) 191 (15%) 18 (1%) 4 12
CHF or PE 779 482 (62%) 95 (12%) 191 (25%) 2 9
PTCA 386 271 (70%) 110 (29%) 0 2 3
Outcome event rates are noted as absolute numerical frequencies (relative % of total number of events in specific category), unless otherwise indicated. Pts 5
patients; other abbreviations as in Tables 1 and 4.
Table 6. Clinical Outcomes in Surgically and Nonsurgically Treated Patients After Acute MI Patients, Adjusted to Eliminate Early Deaths
After 24 h After 48 h After 72 h After 96 h
No CABG CABG No CABG CABG No CABG CABG No CABG CABG
Shock 563 121 327 96 219 71 164 61
(1.6%) (3.6%) (0.9%) (2.9%) (0.6%) (2.2%) (0.5%) (1.9%)
Reinfarction 1104 245 931 222 723 178 562 146
(3.1%) (7.1%) (2.6%) (6.5%) (2.1%) (5.3%) (1.6%) (4.4%)
Ischemia 4,047 831 3,123 666 2,359 513 1,762 381
(12.1%) (27.3%) (9.7%) (23.2%) (7.5%) (18.9%) (5.7%) (14.8%)
CHF 2,498 397 1,464 296 921 236 647 194
(7.5%) (12.7%) (4.6%) (9.8%) (2.9%) (8.0%) (2.1%) (6.7%)
Stroke 245 39 172 33 128 31 102 28
(0.7%) (1.1%) (0.5%) (1.0%) (0.4%) (0.9%) (0.3%) (0.8%)
PTCA 5,972 247 5,431 226 4,715 196 3,901 152
(18%) (7%) (17%) (7%) (15%) (6%) (13%) (5%)
Death 1,438 144 1,071 122 880 116 743 107
(4.0%) (4.1%) (3.0%) (3.5%) (2.5%) (3.3%) (2.1%) (3.1%)
Patients who died before the designated time point of analysis (24, 48, 72 or 96 h) were eliminated from the calculation of event rates. Outcome event rates are
noted as absolute numerical frequencies (relative %). Abbreviations as in Tables 1 and 4.
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ing on a clinically unstable patient. Although the operative
mortality rate of patients undergoing CABG within the first
several days of acute MI is higher than in those who had
CABG later in their hospital course, it is not clear that the
mortality rate of these critically ill patients would be lower if
CABG were deferred or not performed. Indeed, although
Figure 4. One-year survival rate
(Kaplan-Meier plot) in coronary artery
bypass graft surgery (CABG)-treated
and non–CABG-treated groups. A third
plot shows survival in the non–CABG-
treated patients who were alive at 8 days
(mean time of CABG) after onset of
symptoms.
Table 7. Multivariable Analysis Predicting 30-Day Mortality for Patients Undergoing Bypass Surgery*
Variable
Death
Wald Chi-Square† p ValueYes No
IRA n 5 135 n 5 3,290 3.59 (4 df) 0.4650
LAD 51 (37.8%) 1,236 (37.6%)
LCx 11 (8.2%) 309 (9.4%)
RCA 58 (43.0%) 1,465 (44.5%)
LMCA 5 (3.7%) 44 (1.3%)
Other 10 (7.4%) 236 (7.2%)
VSD 14/138 (10.1%) 21/3,317 (0.63%) 22.11 ,0.0001
Acute mitral regurgitation 16/138 (11.6%) 87/3,316 (2.6%) 5.25 0.0219
Days to CABG n 5 138 n 5 3,298 35.82 (2 df) ,0.0001
5 (2, 9) 7 (5, 11) Nonlinear at 4 days
No. of diseased vessels n 5 113 n 5 2,748 0.33 0.5678
0 1 (0.88%) 12 (0.44%)
1 17 (15.0%) 335 (12.2%)
2 36 (31.9%) 1,037 (37.7%)
3 59 (52.2%) 1,364 (49.6%)
LVEF n 5 88 n 5 2,458 7.78 0.0053
45 (35, 53) 50 (40, 60)
Region n 5 138 n 5 3,323 2.94 (4 df) 0.5671
U.S. 118 (85.5%) 2,884 (86.8%)
Europe 9 (6.5%) 200 (6.0%)
Canada 7 (5.1%) 98 (3.0%)
Aust/NZ 2 (1.4%) 80 (2.4%)
Israel 2 (1.4%) 61 (1.8%)
Logit GUSTO n 5 138 n 5 3,323 48.31 ,0.0001
22.3 (23.1, 21.4) 23.2 (24.0, 22.5)
*n5 3,461 (deceased 138 [4.0%], alive 3,323 [96.0%]). Values presented are number (%) of patients or median (25th,
75th percentiles). †Model chi-square value 183.76 (15 degrees of freedom [df]), p value ,0.0001, receiver/operating
characteristic curve index 0.782. Aust 5 Australia; GUSTO 5 Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries; NZ 5 New Zealand; U.S. 5 United States; other abbreviations
as in Tables 1, 2 and 4.
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patients with acute ventricular septal defect were at high risk
for operative mortality, patients treated surgically fared better
(30-day mortality rate 50%; 1-year mortality rate 53%) than
those managed medically (30-day mortality rate 79%; 1-year
mortality rate 83%) (11). Patients with left ventricular dysfunc-
tion also have a high operative mortality rate but enjoy a
substantial survival benefit with CABG (12).
A higher incidence of nonfatal events, including recurrent
ischemia and infarction, shock and congestive heart failure,
was seen in the surgically revascularized group. However, the
majority of events occurred before the time of CABG and thus
constituted indications for CABG rather than consequences of
the operation. Patients undergoing CABG had slightly higher
overall baseline morbidity as well as median predicted mortal-
ity on the basis of factors found to be predictive of survival.
However the mean predicted mortality was lower than that of
the nonsurgical group, reflecting the fact that very elderly or
profoundly hemodynamically compromised patients were very
unlikely to be selected for CABG.
A total of 8,519 patients in the nonsurgical group and 386
patients in the surgical group underwent percutaneous revas-
cularization. Because of the complexity of this issue and the
variety of circumstances under which percutaneous revascular-
ization was used, and the primary importance of examining the
effect of CABG on the treatment effect of thrombolytic
therapy, the details of outcome in the patients undergoing
percutaneous revascularization will be included in a separate
report. Including or excluding these patients from the nonsur-
gical group made no substantive difference in the estimate of
excess risk in the surgical group in the first year.
Limitations of the study. There are several potential
sources of bias in this analysis. Although patients were ran-
domized to the various thrombolytic treatments, surgical inter-
vention was at the discretion of the clinician. The amount of
data that could be realistically collected by the case report
forms precluded a comprehensive understanding of what fac-
tors predisposed patients to be referred for CABG after
admission or after attempted percutaneous revascularization.
During the first few days of enrollment, decisions as to need for
and timing of operation were most likely based on the severity
of clinical symptoms; that is, patients who did not respond to
thrombolytic therapy may have been directed toward early
surgical intervention. Later in the index hospital period,
CABG may have been indicated by more extensive or gener-
alized disease.
An attempt was made to adjust for differences in baseline
characteristics that have been found to be predictive of death,
but statistical adjustment cannot compensate completely for
the differences in the acuity and severity of illness between the
surgical and nonsurgical groups. In particular, complete data
regarding coronary anatomy and left ventricular function were
not available for all patients, and therefore it was not possible
to adjust for differences in these clinical characteristics. It is
possible that the significance of CABG in the time-dependent
covariate model would have been diminished if left ventricular
function and the severity and distribution of coronary disease
were taken into account. Details regarding additional surgical
procedures, valve repair or replacement, aneurysm resection
or carotid endarterectomy, often performed at the time of
revascularization, are also limited. Associated procedures may
have increased the operative risk and affected long-term
outcome.
Another obvious bias is that some patients may not survive
long enough to undergo CABG, and all these patients by
default are medically treated. It is difficult to account for the
effect of these early deaths when trying to understand the
impact of CABG on outcome. We attempted to compensate
for this influence in two ways: 1) by eliminating patients from
the analysis who died shortly after enrollment, and 2) by
constructing the time-dependent covariate model (which in-
cluded all patients). Results from these two approaches were
similar, and both showed an increased relative risk for 30-day
mortality for patients undergoing surgical revascularization
compared with those treated nonsurgically.
Finally, the excess mortality observed in patients undergo-
ing CABG can be interpreted as an association, but causality
cannot be assumed or proved. Patients requiring surgical
revascularization after acute MI and thrombolysis were at
increased risk for mortality at 30 days and at 1 year, but this
analysis cannot completely separate excess mortality resulting
from complications related to the surgical procedure from the
added disease burden prompting early surgical intervention.
Clinical implications. Although thrombolytic therapy re-
sults in improved survival in patients with acute MI, it does not
cure or slow the progression of atherosclerotic heart disease.
Untreated individuals remain at high risk for recurrent isch-
emic events and infarction, with significant ischemia docu-
mented in 10% to 35% of patients and reinfarction in 2.5% to
5.4% (13–17). Patients experiencing recurrent ischemic events
are at increased risk for hypotension, congestive heart failure,
conduction abnormalities and death (18). Many patients can
be managed medically, but a substantial number are ultimately
referred for percutaneous or surgical revascularization. A
number of studies have examined acute and long-term out-
come in patients with acute MI undergoing CABG, but there
are limited randomized data from the prethrombolytic era and
no randomized studies evaluating the safety and efficacy of
CABG in patients after thrombolysis.
Previously published investigations report in-hospital mor-
tality rates for CABG after acute MI, ranging from 2.6% (19)
to 6.7% (20,21). A recent retrospective analysis of 2,175
patients undergoing CABG at a California health maintenance
organization from January 1990 through April 1993 failed to
show any increase in mortality and morbidity for the 530
patients who underwent CABG within 1 month of acute MI,
with operative mortality ranging from a low of 0% in 30
patients operated on between 24 and 72 h to a high of 4.4% in
23 patients operated on within 24 h of acute MI (22). The
operative mortality rate in 1,645 patients without a recent
infarction was 1.9%. In a small randomized trial (23) compar-
ing CABG with medical treatment in 68 patients presenting
within 4 h of acute MI, the 3-month mortality rate for patients
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treated with CABG was 2.9%. Medical treatment alone, which
did not include thrombolytic therapy, was associated with a
20.6% mortality rate.
These data confirm those of other investigators that surgical
revascularization is accomplished with acceptable mortality
after acute MI. Although complications associated with the
perioperative period may negatively impact overall short-term
mortality rates, many patients experience substantial benefit
from early augmentation of myocardial perfusion. Better de-
lineation of the specific subpopulations that stand to improve
the most from costly strategies, such as CABG, will be
necessary as strategies for health care cost containment are
reevaluated.
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